Nasdaq · CIK 0001055726
INO INOVIO PHARMACEUTICALS, INC.
Insider trading from SEC Form 4. Last filing May 21, 2026.
INOVIO PHARMACEUTICALS, INC. (INO) has 48 SEC Form 4 filings on file from 11 insiders, the latest filed on May 21, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
11
with a Form 4 at this company
Signals
Open-market buys and sells at INOVIO PHARMACEUTICALS, INC., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The newest 50 of 155 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 20, 2026 | Lota S. Zoth director | AGrant or award Common Stock Optionsderivative | +41,800 | $0.00 | $0 | 41,800 | May 21, 2026 |
| May 20, 2026 | Laurent Humeau Chief Scientific Officer | MOption exercise Common Stock | +6,027 | - | - | 48,986 | May 21, 2026 |
| May 20, 2026 | Wendy L Yarno director | AGrant or award Common Stock Optionsderivative | +41,800 | $0.00 | $0 | 41,800 | May 21, 2026 |
| May 20, 2026 | Simon X Benito director | AGrant or award Common Stock Optionsderivative | +41,800 | $0.00 | $0 | 41,800 | May 21, 2026 |
| May 20, 2026 | Jacqueline Elizabeth Shea Chief Executive Officer | MOption exercise Common Stock | +28,296 | - | - | 123,327 | May 21, 2026 |
| May 20, 2026 | Roger D Dansey director | AGrant or award Common Stock Optionsderivative | +41,800 | $0.00 | $0 | 41,800 | May 21, 2026 |
| May 20, 2026 | Peter Kies CFO | MOption exercise Common Stock | +8,700 | - | - | 47,542 | May 21, 2026 |
| May 20, 2026 | Jay Shepard director | AGrant or award Common Stock Optionsderivative | +41,800 | $0.00 | $0 | 41,800 | May 21, 2026 |
| May 20, 2026 | David B. Weiner director | AGrant or award Common Stock Optionsderivative | +41,800 | $0.00 | $0 | 41,800 | May 21, 2026 |
| May 20, 2026 | Ann Calby Miller director | AGrant or award Common Stock Optionsderivative | +41,800 | $0.00 | $0 | 41,800 | May 21, 2026 |
| May 20, 2026 | Michael John Sumner Chief Medical Officer | MOption exercise Common Stock | +9,450 | - | - | 44,731 | May 21, 2026 |
| May 20, 2026 | Michael John Sumner Chief Medical Officer | FTax withholding Common Stock | -2,693 | $1.23 | $3,312 | 42,038 | May 21, 2026 |
| May 20, 2026 | Lota S. Zoth director | AGrant or award Restricted Stock Unitderivative | +34,200 | $0.00 | $0 | 34,200 | May 21, 2026 |
| May 20, 2026 | Roger D Dansey director | AGrant or award Restricted Stock Unitderivative | +34,200 | $0.00 | $0 | 34,200 | May 21, 2026 |
| May 20, 2026 | Simon X Benito director | AGrant or award Restricted Stock Unitderivative | +34,200 | $0.00 | $0 | 34,200 | May 21, 2026 |
| May 20, 2026 | Jay Shepard director | AGrant or award Restricted Stock Unitderivative | +34,200 | $0.00 | $0 | 34,200 | May 21, 2026 |
| May 20, 2026 | Laurent Humeau Chief Scientific Officer | FTax withholding Common Stock | -2,163 | $1.23 | $2,660 | 46,823 | May 21, 2026 |
| May 20, 2026 | David B. Weiner director | AGrant or award Restricted Stock Unitderivative | +34,200 | $0.00 | $0 | 34,200 | May 21, 2026 |
| May 20, 2026 | Wendy L Yarno director | AGrant or award Restricted Stock Unitderivative | +34,200 | $0.00 | $0 | 34,200 | May 21, 2026 |
| May 20, 2026 | Ann Calby Miller director | AGrant or award Restricted Stock Unitderivative | +34,200 | $0.00 | $0 | 34,200 | May 21, 2026 |
| May 20, 2026 | Jacqueline Elizabeth Shea Chief Executive Officer | FTax withholding Common Stock | -12,306 | $1.23 | $15k | 111,021 | May 21, 2026 |
| May 20, 2026 | Peter Kies CFO | FTax withholding Common Stock | -4,688 | $1.23 | $5,766 | 42,854 | May 21, 2026 |
| May 20, 2026 | Michael John Sumner Chief Medical Officer | MOption exercise Restricted Stock Unitderivative | -9,450 | $0.00 | $0 | 18,900 | May 21, 2026 |
| May 20, 2026 | Jacqueline Elizabeth Shea Chief Executive Officer | MOption exercise Restricted Stock Unitderivative | -28,296 | $0.00 | $0 | 56,592 | May 21, 2026 |
| May 20, 2026 | Laurent Humeau Chief Scientific Officer | MOption exercise Restricted Stock Unitderivative | -6,027 | $0.00 | $0 | 12,054 | May 21, 2026 |
| May 20, 2026 | Michael John Sumner Chief Medical Officer | AGrant or award Common Stock Optionderivative | +46,876 | $0.00 | $0 | 46,876 | May 21, 2026 |
| May 20, 2026 | Laurent Humeau Chief Scientific Officer | AGrant or award Common Stock Optionderivative | +34,160 | $0.00 | $0 | 34,160 | May 21, 2026 |
| May 20, 2026 | Jacqueline Elizabeth Shea Chief Executive Officer | AGrant or award Common Stock Optionderivative | +123,760 | $0.00 | $0 | 123,760 | May 21, 2026 |
| May 20, 2026 | Peter Kies CFO | MOption exercise Restricted Stock Unitderivative | -8,700 | $0.00 | $0 | 17,400 | May 21, 2026 |
| May 20, 2026 | Michael John Sumner Chief Medical Officer | AGrant or award Restricted Stock Unitderivative | +37,684 | $0.00 | $0 | 37,684 | May 21, 2026 |
| May 20, 2026 | Laurent Humeau Chief Scientific Officer | AGrant or award Restricted Stock Unitderivative | +27,440 | $0.00 | $0 | 27,440 | May 21, 2026 |
| May 20, 2026 | Jacqueline Elizabeth Shea Chief Executive Officer | AGrant or award Restricted Stock Unitderivative | +100,240 | $0.00 | $0 | 100,240 | May 21, 2026 |
| May 20, 2026 | Peter Kies CFO | AGrant or award Common Stock Optionderivative | +39,760 | $0.00 | $0 | 39,760 | May 21, 2026 |
| May 20, 2026 | Peter Kies CFO | AGrant or award Restricted Stock Unitderivative | +32,480 | $0.00 | $0 | 32,480 | May 21, 2026 |
| May 15, 2026 | Laurent Humeau Chief Scientific Officer | MOption exercise Common Stock | +4,771 | - | - | 44,671 | May 18, 2026 |
| May 15, 2026 | Peter Kies CFO | MOption exercise Common Stock | +4,771 | - | - | 41,413 | May 18, 2026 |
| May 15, 2026 | Jacqueline Elizabeth Shea Chief Executive Officer | MOption exercise Common Stock | +17,744 | - | - | 102,748 | May 18, 2026 |
| May 15, 2026 | Michael John Sumner Chief Medical Officer | MOption exercise Common Stock | +2,385 | - | - | 35,961 | May 18, 2026 |
| May 15, 2026 | Laurent Humeau Chief Scientific Officer | FTax withholding Common Stock | -1,712 | $1.30 | $2,226 | 42,959 | May 18, 2026 |
| May 15, 2026 | Peter Kies CFO | FTax withholding Common Stock | -2,571 | $1.30 | $3,342 | 38,842 | May 18, 2026 |
| May 15, 2026 | Jacqueline Elizabeth Shea Chief Executive Officer | FTax withholding Common Stock | -7,717 | $1.30 | $10k | 95,031 | May 18, 2026 |
| May 15, 2026 | Michael John Sumner Chief Medical Officer | FTax withholding Common Stock | -680 | $1.30 | $884 | 35,281 | May 18, 2026 |
| May 15, 2026 | Laurent Humeau Chief Scientific Officer | MOption exercise Restricted Stock Unitderivative | -4,771 | $0.00 | $0 | 0 | May 18, 2026 |
| May 15, 2026 | Jacqueline Elizabeth Shea Chief Executive Officer | MOption exercise Restricted Stock Unitderivative | -17,744 | $0.00 | $0 | 0 | May 18, 2026 |
| May 15, 2026 | Michael John Sumner Chief Medical Officer | MOption exercise Restricted Stock Unitderivative | -2,385 | $0.00 | $0 | 0 | May 18, 2026 |
| May 15, 2026 | Peter Kies CFO | MOption exercise Restricted Stock Unitderivative | -4,771 | $0.00 | $0 | 0 | May 18, 2026 |
| Mar 31, 2026 | Michael John Sumner Chief Medical Officer | MOption exercise Common Stock | +4,292 | - | - | 34,799 | Apr 1, 2026 |
| Mar 31, 2026 | Michael John Sumner Chief Medical Officer | FTax withholding Common Stock | -1,223 | $1.74 | $2,128 | 33,576 | Apr 1, 2026 |
| Mar 31, 2026 | Michael John Sumner Chief Medical Officer | MOption exercise Restricted Stock Unitderivative | -4,292 | $0.00 | $0 | 0 | Apr 1, 2026 |
| Mar 4, 2026 | Laurent Humeau Chief Scientific Officer | AGrant or award Common Stock Optionderivative | +26,840 | $0.00 | $0 | 26,840 | Mar 5, 2026 |
50 of 155 rows shown.
Insiders
Everyone who has filed a Form 4 here.
- Simon X Benitodirector
- Roger D Danseydirector
- Laurent HumeauChief Scientific Officer
- Peter KiesCFO
- Ann Calby Millerdirector
- Jacqueline Elizabeth SheaChief Executive Officer
- Jay Sheparddirector
- Michael John SumnerChief Medical Officer
- David B. Weinerdirector
- Wendy L Yarnodirector
- Lota S. Zothdirector
Questions about INO
Answered from the filings on this page, as of the latest one.
Are insiders buying INO?
No. In the last 90 days no insider at INOVIO PHARMACEUTICALS, INC. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade INO on the open market?
No open-market trade has been scored at INOVIO PHARMACEUTICALS, INC.. The latest Form 4 on file was filed on May 21, 2026 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at INOVIO PHARMACEUTICALS, INC.?
11 people have filed a Form 4 at INOVIO PHARMACEUTICALS, INC., among them Simon X Benito (director), Roger D Dansey (director), Laurent Humeau (Chief Scientific Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.